Coloplast A/S (CLPBF)
USD 112.54
(0.0%)
USD 112.54
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 30.86 Billion DKK | 15.74% |
| 2022 | 26.66 Billion DKK | 247.5% |
| 2021 | 7.67 Billion DKK | 25.93% |
| 2020 | 6.09 Billion DKK | 4.71% |
| 2019 | 5.81 Billion DKK | 8.75% |
| 2018 | 5.35 Billion DKK | -12.25% |
| 2017 | 6.09 Billion DKK | 2.68% |
| 2016 | 5.93 Billion DKK | -2.81% |
| 2015 | 6.11 Billion DKK | 49.19% |
| 2014 | 4.09 Billion DKK | 57.84% |
| 2013 | 2.59 Billion DKK | -37.23% |
| 2012 | 4.13 Billion DKK | -12.78% |
| 2011 | 4.74 Billion DKK | 9.75% |
| 2010 | 4.31 Billion DKK | -15.53% |
| 2009 | 5.11 Billion DKK | -10.14% |
| 2008 | 5.69 Billion DKK | 6.36% |
| 2007 | 5.35 Billion DKK | 3.34% |
| 2006 | 5.17 Billion DKK | 52.22% |
| 2005 | 3.4 Billion DKK | 3.87% |
| 2004 | 3.27 Billion DKK | -2.26% |
| 2003 | 3.35 Billion DKK | 14.73% |
| 2002 | 2.92 Billion DKK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 31.94 Billion DKK | -4.56% |
| 2024 Q1 | 33.46 Billion DKK | 8.44% |
| 2024 Q3 | 32.05 Billion DKK | 0.36% |
| 2023 Q3 | 28.59 Billion DKK | 1.16% |
| 2023 Q1 | 29.31 Billion DKK | 9.95% |
| 2023 FY | 30.86 Billion DKK | 15.74% |
| 2023 Q4 | 30.86 Billion DKK | 7.91% |
| 2023 Q2 | 28.26 Billion DKK | -3.57% |
| 2022 Q2 | 27.89 Billion DKK | 185.57% |
| 2022 Q1 | 9.76 Billion DKK | 27.32% |
| 2022 FY | 26.66 Billion DKK | 247.5% |
| 2022 Q3 | 27.91 Billion DKK | 0.05% |
| 2022 Q4 | 26.66 Billion DKK | -4.46% |
| 2021 Q1 | 9.15 Billion DKK | 50.27% |
| 2021 FY | 7.67 Billion DKK | 25.93% |
| 2021 Q4 | 7.67 Billion DKK | -10.06% |
| 2021 Q3 | 8.53 Billion DKK | 2.62% |
| 2021 Q2 | 8.31 Billion DKK | -9.21% |
| 2020 Q4 | 6.09 Billion DKK | -12.37% |
| 2020 Q1 | 7.77 Billion DKK | 33.56% |
| 2020 Q2 | 6.94 Billion DKK | -10.68% |
| 2020 Q3 | 6.95 Billion DKK | 0.16% |
| 2020 FY | 6.09 Billion DKK | 4.71% |
| 2019 Q1 | 6.92 Billion DKK | 29.34% |
| 2019 FY | 5.81 Billion DKK | 8.75% |
| 2019 Q3 | 6.61 Billion DKK | 8.06% |
| 2019 Q4 | 5.81 Billion DKK | -11.99% |
| 2019 Q2 | 6.11 Billion DKK | -11.59% |
| 2018 Q3 | 7.46 Billion DKK | 1.22% |
| 2018 Q1 | 7.48 Billion DKK | 22.7% |
| 2018 Q4 | 5.35 Billion DKK | -28.32% |
| 2018 Q2 | 7.37 Billion DKK | -1.43% |
| 2018 FY | 5.35 Billion DKK | -12.25% |
| 2017 Q3 | 7.28 Billion DKK | -2.12% |
| 2017 Q2 | 7.44 Billion DKK | -14.1% |
| 2017 Q1 | 8.66 Billion DKK | 45.97% |
| 2017 Q4 | 6.09 Billion DKK | -16.34% |
| 2017 FY | 6.09 Billion DKK | 2.68% |
| 2016 Q4 | 5.93 Billion DKK | -12.42% |
| 2016 Q2 | 5.67 Billion DKK | -16.29% |
| 2016 FY | 5.93 Billion DKK | -2.81% |
| 2016 Q3 | 6.78 Billion DKK | 19.4% |
| 2016 Q1 | 6.78 Billion DKK | 11.01% |
| 2015 FY | 6.11 Billion DKK | 49.19% |
| 2015 Q2 | 4.14 Billion DKK | -2.84% |
| 2015 Q1 | 4.26 Billion DKK | 4.2% |
| 2015 Q3 | 4.15 Billion DKK | 0.12% |
| 2015 Q4 | 6.11 Billion DKK | 47.18% |
| 2014 Q2 | 3.43 Billion DKK | 48.34% |
| 2014 Q4 | 4.09 Billion DKK | 10.76% |
| 2014 FY | 4.09 Billion DKK | 57.84% |
| 2014 Q1 | 2.31 Billion DKK | -10.87% |
| 2014 Q3 | 3.69 Billion DKK | 7.78% |
| 2013 Q3 | 2.48 Billion DKK | -33.21% |
| 2013 FY | 2.59 Billion DKK | -37.23% |
| 2013 Q4 | 2.59 Billion DKK | 4.55% |
| 2013 Q2 | 3.71 Billion DKK | -3.53% |
| 2013 Q1 | 3.85 Billion DKK | -6.82% |
| 2012 Q3 | 4.58 Billion DKK | 5.77% |
| 2012 Q4 | 4.13 Billion DKK | -9.78% |
| 2012 FY | 4.13 Billion DKK | -12.78% |
| 2012 Q1 | 4.47 Billion DKK | -5.57% |
| 2012 Q2 | 4.33 Billion DKK | -3.22% |
| 2011 Q3 | 4.5 Billion DKK | 1.17% |
| 2011 FY | 4.74 Billion DKK | 9.75% |
| 2011 Q1 | 4.59 Billion DKK | 6.37% |
| 2011 Q2 | 4.45 Billion DKK | -3.05% |
| 2011 Q4 | 4.74 Billion DKK | 5.19% |
| 2010 Q3 | 4.79 Billion DKK | 5.51% |
| 2010 Q4 | 4.31 Billion DKK | -9.83% |
| 2010 FY | 4.31 Billion DKK | -15.53% |
| 2010 Q2 | 4.54 Billion DKK | -2.7% |
| 2010 Q1 | 4.66 Billion DKK | -8.74% |
| 2009 FY | 5.11 Billion DKK | -10.14% |
| 2009 Q4 | 5.11 Billion DKK | 0.0% |
| 2008 FY | 5.69 Billion DKK | 6.36% |
| 2007 FY | 5.35 Billion DKK | 3.34% |
| 2006 FY | 5.17 Billion DKK | 52.22% |
| 2005 FY | 3.4 Billion DKK | 3.87% |
| 2004 FY | 3.27 Billion DKK | -2.26% |
| 2003 FY | 3.35 Billion DKK | 14.73% |
| 2002 FY | 2.92 Billion DKK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| American Medical Technologies Inc. | 2.34 Million USD | -1313178.669% |
| Ansell Limited | 1.32 Billion USD | -2220.464% |
| Ansell Limited | 1.33 Billion USD | -2216.121% |
| BG Medicine, Inc. | - USD | -Infinity% |
| Biotage AB (publ) | 126.33 Million USD | -24326.586% |
| BioLife Sciences Inc. | - USD | -Infinity% |
| CB Scientific, Inc. | 943.17 Thousand USD | -3271837.674% |
| Psykey, Inc. | 2.47 Million USD | -1247263.096% |
| ConvaTec Group Plc | 2.01 Billion USD | -1429.126% |
| ConvaTec Group Plc | 2.02 Billion USD | -1426.967% |
| Encision Inc. | 1.98 Million USD | -1555368.637% |
| Golden Valley Development, Inc | - USD | -Infinity% |
| Hear AtLast Holdings, Inc. | 3.04 Million USD | -1014871.654% |
| Innovative MedTech Inc. | 6.13 Million USD | -502928.358% |
| LifePoint, Inc. | 2.45 Million USD | -1257352.115% |
| Medite Cancer Diagnostics, Inc. | 10.18 Million USD | -303013.643% |
| Paradigm Medical Industries, Inc. | 3.4 Million USD | -907547.059% |
| QuantRx Biomedical Corporation | - USD | -Infinity% |
| Remedent, Inc. | 3.04 Million USD | -1014923.733% |
| Reflect Scientific, Inc. | 776.32 Thousand USD | -3975018.796% |
| SmileDirectClub, Inc. | 982.26 Million USD | -3041.731% |
| Sector 10, Inc. | 9.84 Million USD | -313344.982% |
| Shandong Weigao Group Medical Polymer Company Limited | 1.35 Billion USD | -2176.304% |
| SheerVision, Inc. | 1.43 Million USD | -2155826.738% |
| United Health Products, Inc. | 1.99 Million USD | -1543773.06% |
| Vasamed, Inc. | 1 Million USD | -3069630.429% |
| Wearable Health Solutions, Inc. | 3.8 Million USD | -811944.36% |
| Yubo International Biotech Limited | 2.91 Million USD | -1058953.016% |